CELYAD ONCOLOGY SA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.3395 EUR | +4.14% |
|
-2.44% | -12.95% |
| Apr. 04 | Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Feb. 09 | Celyad Oncology Seeks Termination of Reporting Obligations to US SEC | MT |
| Sales 2022 | - | Sales 2023 | 102K 108K | Capitalization | 16.16M 17.18M |
|---|---|---|---|---|---|
| Net income 2022 | -40M -42.52M | Net income 2023 | -8M -8.5M | EV / Sales 2022 | - |
| Net cash position 2022 | 12.19M 12.96M | Net cash position 2023 | 5.95M 6.32M | EV / Sales 2023 | 100 x |
| P/E ratio 2022 |
-0.28
x | P/E ratio 2023 |
-1.19
x | Employees | 18 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 92.37% |
More Fundamentals
* Assessed data
More news
Latest transcript on Celyad Oncology SA
More recommendations
More press releases
More news
| 1 day | -2.54% | ||
| 1 week | -6.32% | ||
| Current month | -7.12% | ||
| 1 month | -7.39% | ||
| 3 months | -7.91% | ||
| 6 months | -54.21% | ||
| Current year | -16.41% |
1 week
0.31
0.34
1 month
0.300.38
Current year
0.300.47
1 year
0.301.28
3 years
0.306.02
5 years
0.3018.98
10 years
0.3070.95
| Managers | Title | Age | Since |
|---|---|---|---|
Michel Lussier
FOU | Founder | 67 | 07-07-23 |
David Georges
DFI | Director of Finance/CFO | - | 18-12-31 |
Eytan Breman
CTO | Chief Tech/Sci/R&D Officer | - | 14-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Michel Lussier
FOU | Founder | 67 | 07-07-23 |
Hilde Windels
CHM | Chairman | 59 | 18-05-06 |
Serge Goblet
BRD | Director/Board Member | - | 07-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 0.3395 | +4.14% | 15 243 |
| 24-04-18 | 0.326 | -2.54% | 2,604 |
| 24-04-17 | 0.3345 | -1.47% | 16,912 |
| 24-04-16 | 0.3395 | -0.15% | 10,241 |
| 24-04-15 | 0.34 | +6.25% | 10,091 |
Real-time Euronext Bruxelles, April 18, 2024 at 11:35 am EDT
More quotes
Celyad Oncology SA is a biotechnology company focused on the discovery and development of innovative technologies chimeric antigen receptor (CAR) T-cell therapies. The company is focusing on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property and support the development of next-generation CAR T candidates in solid tumors and hematological malignancies.
Calendar
2024-05-01
- Q1 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -16.41% | 14.4M | |
| -1.82% | 41.35B | |
| +44.25% | 40.38B | |
| +2.56% | 39.05B | |
| -12.11% | 26.67B | |
| +3.09% | 24.07B | |
| -24.16% | 18.36B | |
| +22.12% | 11.6B | |
| -3.74% | 11.68B | |
| +7.75% | 11.15B |
- Stock Market
- Equities
- CYAD Stock
